Who makes HL140 10/10?

HL140 10/10 is developed by Hanlim Pharm. Co., Ltd..

Last reviewed 2026-05-14 · How we verify

HL140 10/10

Hanlim Pharm. Co., Ltd. · Phase 3 active Small molecule

HL140 10/10 is an investigational drug with an undisclosed mechanism of action.

At a glance

Generic name	HL140 10/10
Sponsor	Hanlim Pharm. Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

The specific mechanism of action for HL140 10/10 has not been publicly disclosed, making it difficult to provide a detailed explanation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HL140 10/10 CI brief — competitive landscape report
HL140 10/10 updates RSS · CI watch RSS
Hanlim Pharm. Co., Ltd. portfolio CI